Daiwa Cuts AKESO TP to HKD120, Reiterates Buy; Decline Exceeds Fundamentals

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Daiwa said in a research report that AKESO (09926.HK) -2.150 (-3.354%) Short selling $229.03M; Ratio 31.847% 's global partner SUMMIT Therapeutics announced on the morning of Nov 15 (US Eastern Time) that the US FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for ivonescimab in combination with platinum-based chemotherapy for second-line EGFR-mutant non-small cell lung cancer (2L EGFRm NSCLC), rejecting approval for the indication. The broker said the FDA rejection was not entirely unexpected because the overall survival (OS) endpoint in the HARMONi study did not reach the pre-specified statistical significance threshold in the primary analysis, while OS has now become the most important consideration in oncology drug approvals.

Daiwa noted that AKESO (09926.HK) -2.150 (-3.354%) Short selling $229.03M; Ratio 31.847% 's share price fell 23% yesterday (16 Nov), with the decline exceeding the fundamental impact because 2L EGFRm NSCLC accounts for less than 10% of ivonescimab's US peak sales potential. The broker believed the decline was caused by multiple factors, including weak market sentiment on the day, general investors viewing the FDA rejection as below expectations, and the negative impression created by the October share placement alongside the FDA rejection. The broker believed the adjustment also provided a good entry opportunity, as multiple key data readouts are expected in 2027, including progression-free survival (PFS) and OS data for first-line squamous and non-squamous NSCLC in 1H27.

The broker reiterated its Buy rating on AKESO (09926.HK) -2.150 (-3.354%) Short selling $229.03M; Ratio 31.847% , but removed revenue forecasts for ivonescimab in global 2L EGFRm NSCLC markets after the FDA issued the CRL. It also excluded the value of early-stage pipelines from its discounted cash flow (DCF) target price calculation and raised its weighted average cost of capital (WACC) estimate from 9.4% to 9.7%. The 12-month target price was cut from HKD140 to HKD120. Key downside risks include weaker-than-expected global HARMONi-3 data for ivonescimab and earnings missing expectations. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 12:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.